The results of this analysis revealed that treating patients with hormone receptor (HR) positive breast cancer with PEH regimen had a significantly higher chance to achieve pCR compared with PCH regimen (OR: 3.87, 95%CI: 1.09-13.81, p = 0.033). The gene discussed is NR4A1; the disease is breast cancer.